Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031
BIL also holds an option to increase its equity stake by an additional 15%
_LOGO_256_384.jpg){kind=logo}
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
Ultra-high purity surfactant for biologics and parenteral drug formulations
Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Subscribe To Our Newsletter & Stay Updated
